Head and Neck Squamous Cell Carcinoma Clinical Trials

65 studies are recruiting for head and neck squamous cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

  1. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

    A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    St Vincent's Hospital, Darlinghurst, New South Wales
    Locations
    16 in total
    Run by
    OncoNano Medicine, Inc.
  2. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

    Stage
    Phase 1
    Ages
    18 to 80
    Site
    Providence Medical Foundation (site 209), Santa Rosa, California
    Locations
    15 in total
    Run by
    VM Oncology, LLC
  3. Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

    The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Washington University in St. Louis, St Louis, Missouri
    Locations
    4 in total
    Run by
    Medical University of South Carolina
  4. Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

    Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have favorable outcomes and how well they do depends on the specific details about the patient and their cancer. How well they do isn't as related to the kinds of treatment they get. However, there are significant side …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Maryland Proton Treatment Center, Baltimore, Maryland
    Locations
    5 in total
    Run by
    University of Maryland, Baltimore
  5. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

    This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Southern California, Los Angeles, California
    Locations
    14 in total
    Run by
    Volastra Therapeutics, Inc.
  6. Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

    This early phase I trial compares sodium fluoride F-18 (F-18 NaF) positron emission tomography (PET)/computed tomography (CT) to the standard of care imaging scan (and fludeoxyglucose F-18 [F-18 FDG] PET/CT) for assessing the effects radiation therapy has on the blood vessels in the neck in patient…

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    Emory University Hospital Midtown, Atlanta, Georgia
    Run by
    Emory University
  7. A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

    The purpose of the study is to determine the activity and safety of ACR-368 (prexasertib) in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Participants will receive the study drugs ACR-368 and a low dose of gemcitabine once every 2 weeks in 4-week …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    H. Lee Moffitt Cancer Center and Research Institute
  8. Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

    This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography (SPECT)/computed tomography (CT) and panitumumab-IRDye800 fluorescence imaging during surgery (intraoperative), to…

    Stage
    Phase 1
    Ages
    19 and older
    Site
    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
    Run by
    Vanderbilt-Ingram Cancer Center
  9. A Study of NX-1607 in Adults With Advanced Malignancies

    This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Southern California, Los Angeles, California
    Locations
    17 in total
    Run by
    Nurix Therapeutics, Inc.
  10. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moores Cancer Center UC San Diego Health, La Jolla, California
    Locations
    20 in total
    Run by
    Bicara Therapeutics
  11. A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

    This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantities via the CIVO device.

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    LSU Health Sciences Center, Shreveport, Louisiana
    Run by
    Pure Biologics S.A.
  12. Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy

    This purpose of this study is to examine skin reactions (called radiation dermatitis) that occur during pencil beam scanning (PBS) proton therapy. The researchers will test a unique technique called "Spot Delete" to see if it can reduce skin reactions for head \& neck patients treated with PBS. The…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Thompson Proton Center, Knoxville, Tennessee
    Run by
    Covenant Health Cancer Center
  13. Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

    This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    CHA University Bundang Medical Center, Seongnam,
    Locations
    11 in total
    Run by
    TiumBio Co., Ltd.
  14. Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC

    This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma. These are subjects who have undergone surgery or will be undergoing surgery.

    Stage
    Phase 2
    Ages
    18 to 79
    Site
    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
    Run by
    University of California, Irvine
  15. Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

    This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
    Run by
    Vanderbilt-Ingram Cancer Center

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.